AstraZeneca To Discontine STABILIZE-CKD, DIALIZE-Outcomes Trials Under CRYSTALIZE Programme

(RTTNews) - AstraZeneca (AZN.L, AZN) said it has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma. The company said the decision was made due to substantially increased enrolment timelines and low event rates, respectively, which https://www.nasdaq.com/articles/astrazeneca-to-discontine-stabilize-ckd-dialize-outcomes-trials-under-crystalize-programme